C18H20N4O6.C2HF3O2
Neat
388.38 114.02
2022182-58-5; Thalidomide-O-amido-C3-NH2 TFA; Thalidomide-O-amido-C3-NH2 (TFA); MFCD32215305; N-(3-Aminopropyl)-2-((2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindolin-4-yl)oxy)acetamide 2, 2, 2-trifluoroacetate; N-(3-Aminopropyl)-2-((2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindolin-4-yl)oxy)acetamide trifluoroacetic acid salt; E3 Ligase Ligand-Linker Conjugates 52 (TFA); Thalidomide-O-amido-C3-NH2; N-(3-aminopropyl)-2-[2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindol-4-yl]oxyacetamide;2, 2, 2-trifluoroacetic acid; N-(3-aminopropyl)-2-[2-(2, 6-dioxo-3-piperidyl)-1, 3-dioxo-isoindolin-4-yl]oxy-acetamide;2, 2, 2-trifluoroacetic acid; N-(3-aminopropyl)-2-{[2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxo-2, 3-dihydro-1H-isoindol-4-yl]oxy}acetamide; trifluoroacetic acid; LCZC1078; orb1299532; C20H21F3N4O8; EX-A3944; AKOS037654845; AT18333; HY-115560A; Thalidomide-O-amido-C3-NH2 and TFA salt; AC-37823
N-(3-aminopropyl)-2-[2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindol-4-yl]oxyacetamide;2, 2 and 2-trifluoroacetic acid
InChI=1S/C18H20N4O6.C2HF3O2/c19-7-2-8-20-14(24)9-28-12-4-1-3-10-15(12)18(27)22(17(10)26)11-5-6-13(23)21-16(11)25;3-2(4,5)1(6)7/h1,3-4,11H,2,5-9,19H2,(H,20,24)(H,21,23,25);(H,6,7)